The purpose of this double-blind, randomized control trial was to see if a 2-day course of amoxicillin-clavulanate could reduce the incidence of early ventilator-associated pneumonia in patients undergoing targeted temperature management after an out-of-hospital cardiac arrest with an initial shockable rhythm.
When compared to the placebo group, there was a substantial reduction in the incidence of early ventilator-associated pneumonia in the treatment group, but no reduction in ventilator-free days or death at day 28.
